Compare ClearPoint Neuro Inc (CLPT) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Ryanair Holdings plc — how do they compare? ClearPoint Neuro Inc trades at $14.89 (market cap $454.21M), while Ryanair Holdings plc trades at $59.59 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 65.2× ClearPoint Neuro Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | RYAAY | |
|---|---|---|
Market Cap | $454.21M | $29.63B |
Sector | Health | Industrials |
52-Week High | $29.60 | $73.82 |
52-Week Low | $8.66 | $53.24 |
Enterprise Value | $488.79M | $26.61B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.
RYAAY trades at $60.63, up 1.88% today, but faces a bearish technical signal with support at $58. Fundamentally, it shows strong profitability with a 12.13% net margin and a reasonable P/E of 14.37. Recent Q1 2026 earnings beat expectations despite a 34% profit decline due to lower fares and higher fuel costs (Reuters, 2026-07-20). The company maintains a robust balance sheet with $3.96B in cash and announced a strategic AI partnership with Google Cloud to enhance operations.
The outlook is mixed; analyst consensus is bullish (62.5% buy ratings), citing long-term advantages from industry consolidation and a strong financial position. However, near-term risks include volatile fuel prices, competitive fare pressures, and geopolitical tensions affecting travel demand. The stock presents a value opportunity for patient investors, but requires monitoring of operational execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
